
The impact of COVID-19 today spread across to virtually all industries, including manufacturing, distribution, construction, pharmaceuticals, and tourism. As such, despite some differences amongst industries, the closing of cross-border M&A contracts is also being delayed. Even when a cross-border M&A contract has been executed, the price of the contract of the sale is often adjusted or the closing of the contract is being delayed frequently.
In relation to cross-border M&A transactions, COVID-19 is causing the parties thereof to ① adjust or revalue the value of the target company, and ② change the operation of the target company. Also, ③ the seller and buyer, who entered into a cross-border M&A contract before the COVID-19 pandemic, are arguing over the provision, “there shall be no material adverse change (MAC) occurred in relation to the target company,” which takes effect in relation to the method of distributing risks that occur after the execution of the contract and before the closing of the transaction between the transaction parties on the contract.
This time, we will dive into the matters the seller and buyer must consider in cross-border M&A transactions in general. Please note that this article is an opinion of the attorneys of DOWOO LAW, which is subject to differing opinions of experts and cannot be used as a rule of interpretation in transactions.
Impact of COVID-19 on cross-border M&A contracts—what are the general considerations? 
“Material Adverse Change” (MAC) means a case where
changes have occurred to the business or financial circumstance of the target company after executing an M&A contract and before concluding the transaction. An absence of such MAC is generally included as a prerequisite for concluding the relevant transaction in an M&A contract. If a cross-border M&A contract is yet to be executed, a seller shall include a provision on COVID-19 into the MAC provision, emphasizing the risk of COVID-19 as an important matter in the preparation and negotiation stage of the contract in the first place.
In the case of a deal where the COVID-19 pandemic broke out after the execution of a cross-border M&A contract and before the closing of the transaction, it is likely that the seller and buyer signed the contract without considering COVID-19. However,
unfortunately, as COVID-19 has occurred immediately before the closing, the buyer will either try to become unbound from the contract even by paying the penalty (Reverse Termination Fee) or at least to adjust thereof via the procedure of adjusting the acquisition price of the contract. If the acquisition price is determined by the Completion Adjustment Model, under which the price may be partially adjusted prior to the closing, there may be room for readjustment for the buyer.
However, as the contract has been executed, it is difficult to readjust the acquisition price by reflecting all of the deterioration in the value of the target company caused by COVID-19 as it is today. In executing a cross-border M&A contract, what should be checked in each case before and after the outbreak of COVID-19?
What should buyers and sellers specifically consider when the COVID-19 outbreak occurred after the execution of a cross-border M&A contract but before the closing? ① Acknowledging change of circumstances The matters that must be checked first include any issue in the distribution network of the target company such as raw materials or intermediate goods, the occurrence of labor conflicts due to large scale cut-back by the target company, the extent of the decline in customers when the target company is directly influenced by COVID-19 as in the tourism and hospitality industries, the extent of difference between the existing due diligence result and the future profit structure of the target company, and whether one party may claim indemnification of the two parties when there is a default between the target company or with existing clients of the target company.
② Acquisition financing The buyer must review whether a financial institution can still provide the necessary funding for the acquisition after the COVID-19 outbreak. If this is no longer possible, the buyer should find another way to obtain the funds.
③ Identifying the insurance subscription status of the target company Because the buyer has an interest in the adequacy of the coverage of the insurance that the target company subscribed to previously even after the COVID-19 outbreak, the seller would also need to have enough discussion and consultation about the target company’s insurance status with the buyer for the success of the deal.
④ Reviewing contractual relationships of the target company with existing transaction parties Considering the controversy over whether COVID-19 is a cause of exemption as force majeure, the buyer must review whether the target company can claim the force majeure cause of exemption under existing contracts with its partners such as existing third-party suppliers, or can argue the cancellation of the contract thereof. It should also be carefully considered whether the target company appropriately adhere to the duty to notify within a certain period if any. The seller must also fully communicate and cooperate with the buyer regarding the above matters for a successful deal.
⑤ Matters to review in a cross-border M&A contract A. Pre-Closing Covenant As a general pre-closing covenant, a clause is included that requires the seller to maintain the normal business condition. Thus, the seller must review whether the measures it plans to take in response to the COVID-19 pandemic before the closing violate the above covenants and take necessary measures.
B. Review additional disclosures Bring-down warranty prescribes that the representation and guarantees provided at the date of execution of the contract are true and accurate as of the date of the closing as a prerequisite of the transaction. Thus, the seller must carefully consider any additional disclosures to be made to the buyer in this regard and, if so, what should be disclosed.
C. Acquisition price
Even in the case of the Locked-Box Model whereby an acquisition price cannot be changed until the closing, a discussion for price adjustment may be necessary if there is a material change in the basis of the acquisition price set at the time of executing the contract.
⑥ Delaying closing date It must also be reviewed whether the final meeting for the closing can actually take place or should be delayed due to the COVID-19 outbreak.
When the COVID-19 pandemic has become a public issue before the execution of a cross-border M&A contract—what should the buyer and seller check? Parties related to M&A transactions must acknowledge that the M&A contract may be delayed or even unreached. The buyer may not voluntarily sign the M&A contract for reasons such as that acquisition financing is difficult, or the timing is bad due to uncertainty regarding the target company. The seller will experience difficulties in the possible proposal to the buyer for finding other options to close the deal. Of course, the acquisition of the target company is not always delayed due to the COVID-19 outbreak.
For instance, if the target company is in industries such as healthcare, delivery, or IT, which is not adversely affected by COVID-19 whatsoever or rather coming to the fore, the acquisition may rather increase in the short to medium term. It is noteworthy that such a phenomenon is occurring even more often in M&A transactions via competitive bidding.
Please do not hesitate to contact us (call or email) at the contact below if you have any further inquiries or need additional data regarding this Article. Specialized attorneys of the Corporate Legal Team of DOWOO HWASAN LAW will be there to help you.